Vanguard Group
NERV icon

Vanguard Group’s Minerva Neurosciences NERV Stock Holding History

Vanguard Group’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.01M Hold
252,029
– – ﹤0.01% 3774
2025
Q3 		$534K Sell
252,029
-31
-0% -$63 ﹤0.01% 3928
2025
Q2 		$434K Hold
252,060
– – ﹤0.01% 3951
2025
Q1 		$429K Hold
252,060
– – ﹤0.01% 3920
2024
Q4 		$560K Hold
252,060
– – ﹤0.01% 3918
2024
Q3 		$673K Hold
252,060
– – ﹤0.01% 3895
2024
Q2 		$804K Hold
252,060
– – ﹤0.01% 3865
2024
Q1 		$650K Buy
252,060
+46,906
+23% +$288K ﹤0.01% 3950
2023
Q4 		$1.26M Hold
205,154
– – ﹤0.01% 3747
2023
Q3 		$1.42M Hold
205,154
– – ﹤0.01% 3712
2023
Q2 		$1.88M Buy
205,154
+11,216
+6% +$59.2K ﹤0.01% 3681
2023
Q1 		$310K Hold
193,938
– – ﹤0.01% 4239
2022
Q4 		$308K Buy
193,938
+30,344
+19% +$131K ﹤0.01% 4216
2022
Q3 		$1.51M Sell
163,594
-328,483
-67% -$1.95M ﹤0.01% 3858
2022
Q2 		$1.63M Sell
492,077
-3
-0% -$12 ﹤0.01% 3896
2022
Q1 		$3.27M Sell
492,080
-11,138
-2% -$68.3K ﹤0.01% 3733
2021
Q4 		$3.23M Sell
503,218
-9,552
-2% -$89.9K ﹤0.01% 3843
2021
Q3 		$7.14M Buy
512,770
+414
+0.1% +$6.23K ﹤0.01% 3438
2021
Q2 		$9.51M Sell
512,356
-40,478
-7% -$871K ﹤0.01% 3232
2021
Q1 		$12.9M Buy
552,834
+21,574
+4% +$539K ﹤0.01% 3014
2020
Q4 		$9.95M Buy
531,260
+23,834
+5% +$600K ﹤0.01% 2999
2020
Q3 		$12.9M Buy
507,426
+108,785
+27% +$2.94M ﹤0.01% 2663
2020
Q2 		$11.5M Buy
398,641
+187,421
+89% +$11M ﹤0.01% 2700
2020
Q1 		$10.2M Buy
211,220
+1,595
+0.8% +$96.2K ﹤0.01% 2616
2019
Q4 		$11.9M Sell
209,625
-2,909
-1% -$128K ﹤0.01% 2773
2019
Q3 		$13.2M Buy
212,534
+5,785
+3% +$328K ﹤0.01% 2686
2019
Q2 		$9.31M Buy
206,749
+186
+0.1% +$9.31K ﹤0.01% 2900
2019
Q1 		$13M Buy
206,563
+6,266
+3% +$377K ﹤0.01% 2688
2018
Q4 		$10.8M Buy
200,297
+8,098
+4% +$593K ﹤0.01% 2740
2018
Q3 		$19.3M Buy
192,199
+2,120
+1% +$159K ﹤0.01% 2593
2018
Q2 		$12.5M Buy
190,079
+14,469
+8% +$879K ﹤0.01% 2785
2018
Q1 		$8.78M Buy
175,610
+11,482
+7% +$552K ﹤0.01% 2881
2017
Q4 		$7.94M Buy
164,128
+6,784
+4% +$336K ﹤0.01% 2932
2017
Q3 		$9.57M Buy
157,344
+23,064
+17% +$1.32M ﹤0.01% 2830
2017
Q2 		$9.51M Buy
134,280
+16,868
+14% +$1.09M ﹤0.01% 2799
2017
Q1 		$7.61M Buy
117,412
+13,859
+13% +$1.08M ﹤0.01% 2875
2016
Q4 		$9.73M Buy
103,553
+9,450
+10% +$965K ﹤0.01% 2765
2016
Q3 		$10.6M Buy
94,103
+18,532
+25% +$1.8M ﹤0.01% 2659
2016
Q2 		$6.17M Buy
75,571
+10,483
+16% +$666K ﹤0.01% 2873
2016
Q1 		$3.2M Buy
65,088
+52,837
+431% +$2.26M ﹤0.01% 3185
2015
Q4 		$595K Buy
12,251
+4,531
+59% +$189K ﹤0.01% 3788
2015
Q3 		$324K Buy
7,720
+324
+4% +$14.9K ﹤0.01% 3950
2015
Q2 		$343K Buy
7,396
+747
+11% +$31.9K ﹤0.01% 3956
2015
Q1 		$266K Buy
+6,649
New +$275K ﹤0.01% 3951

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group's NERV Position: Q4 2025 in Review

Vanguard Group held its Minerva Neurosciences (NERV) position steady in Q4 2025 at 252,029 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #3774.

Vanguard Group first reported a position in NERV in Q1 2015 and has held it in 44 quarters since. The position peaked at $19.3M in Q3 2018. 33 funds tracked by Wall St. Rank hold NERV as of Q4 2025.

  • Vanguard Group held 252,029 shares of Minerva Neurosciences worth $1.01M as of Q4 2025.
  • Vanguard Group left its Minerva Neurosciences share count unchanged in Q4 2025.
  • Minerva Neurosciences made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3774 holding.
  • Vanguard Group first reported a position in Minerva Neurosciences in Q1 2015 and has held it in 44 quarters since.
  • Vanguard Group's Minerva Neurosciences position peaked at $19.3M in Q3 2018.
  • 33 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.